Company: LDDD
Filing Date: 2025-09-26
Form Type: 10-K
Source: 0001213900-25-091988
Chunk: 8

Company: Longduoduo Co Ltd
Filing Date: 2025-09-26
Form: 10-K
Item: Item 1
Chunk 8
---
 or an exchange, we will be required to obtain the approval of the PRC government
for a business combination, the issuance of our common stock, or maintaining our status as a publicly listed company outside China.

5

Our
Business

Our
operating subsidiaries, Julong, Longduoduo Health Technology, Qingguo, Rongbin, Chengheng, Tianju and Yihua, serve, for some customers,
as sales agents for third-party healthcare service providers and, for other customers, as distributors of services provided by third-party
healthcare service providers. In both arrangements, the health care providers provide comprehensive and high-quality preventive healthcare
solutions, including disease screening, healthcare treatments, healthcare products and other services. The Company mainly focuses on
prevention of myocardial infarction, cerebral infarction, hemiplegia, and cardiovascular and cerebrovascular diseases.

 Commissioned
Sales

Since
June of 2023, our operating subsidiaries have been primarily engaged in selling health maintenance services provided by Inner Mongolia
Honghai Health Management Co., Ltd. (“Honghai”). During the year ended June 30, 2025, over 97% of our gross revenue came
from commissions earned through our agency relationship with Honghai. Each operating subsidiary is party to a separate Sales Agency Agreement
with Honghai, each dated June 20, 2023 and expiring on June 20, 2026, although the content of the five Sales Agency Agreements are identical
but for the name of the agent: Longduoduo Health Technology Co., Ltd, Inner Mongolia Rongbin Health Consulting Co., Ltd, Inner Mongolia
Chengheng Health Consulting Co., Ltd, Inner Mongolia Qinguo Health Consulting Co., Ltd. or Inner Mongolia Tianju Health Consulting Company
Limited. Among the principal terms of the Sales Agency Agreements are:

●Honghai
is responsible for developing and providing services, and our operating subsidiary (the “Agent”) is responsible for promoting
and selling the services.

●When
the Sales Agency Agreement was signed, the specific services to be marketed were: trioxygen autotransfusion, awakening brain and dredging
collaterals, double blood purification in German technology, hyperbaric trioxygen, colon hydrotherapy, intestinal flora transplantation,
custom-made Juncao and combinations of these services.

●If
Honghai develops new services, the Agent will have the option to market the new services at a price to be negotiated with Honghai in